RPG Life Sciences Limited (NSE:RPGLIFE)
India
· Delayed Price · Currency is INR 1,872.30
-3.60 (-0.19%)
At close: Mar 6, 2026
RPG Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Revenue | 6,737 | 6,534 | 5,821 | 5,128 | 4,402 | 3,891 | Upgrade
|
| Revenue Growth (YoY) | 5.71% | 12.26% | 13.50% | 16.50% | 13.11% | 3.61% | Upgrade
|
| Cost of Revenue | 2,455 | 2,192 | 1,893 | 1,758 | 1,469 | 1,356 | Upgrade
|
| Gross Profit | 4,283 | 4,342 | 3,928 | 3,370 | 2,932 | 2,535 | Upgrade
|
| Selling, General & Admin | 1,629 | 1,523 | 1,542 | 1,346 | 1,153 | 1,055 | Upgrade
|
| Other Operating Expenses | 1,245 | 1,211 | 1,104 | 988.4 | 915.5 | 779.5 | Upgrade
|
| Operating Expenses | 3,085 | 2,948 | 2,817 | 2,489 | 2,225 | 1,999 | Upgrade
|
| Operating Income | 1,198 | 1,394 | 1,111 | 881 | 707.4 | 536.6 | Upgrade
|
| Interest Expense | -6.8 | -6.2 | -4.5 | -3.1 | -5.2 | -7.9 | Upgrade
|
| Interest & Investment Income | 32.1 | 32.1 | 14.2 | 27.3 | 13.3 | 3.2 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.6 | 1.6 | 0.1 | 5 | 7.3 | 4 | Upgrade
|
| Other Non Operating Income (Expenses) | 103.1 | 47.5 | 47.2 | 14.4 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 1,328 | 1,469 | 1,168 | 924.6 | 722.8 | 535.9 | Upgrade
|
| Gain (Loss) on Sale of Investments | 12 | 12 | 0.1 | - | 8.9 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 22.1 | 22.1 | 10.5 | -7.8 | - | -0.1 | Upgrade
|
| Other Unusual Items | 1,127 | 826 | - | - | - | - | Upgrade
|
| Pretax Income | 2,489 | 2,329 | 1,178 | 916.8 | 731.7 | 535.8 | Upgrade
|
| Income Tax Expense | 462.8 | 496.4 | 301.8 | 240.4 | 216.9 | 135.8 | Upgrade
|
| Earnings From Continuing Operations | 2,026 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade
|
| Net Income | 2,026 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade
|
| Net Income to Common | 2,026 | 1,832 | 876.6 | 676.4 | 514.8 | 400 | Upgrade
|
| Net Income Growth | 156.06% | 109.03% | 29.60% | 31.39% | 28.70% | 37.88% | Upgrade
|
| Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 | 17 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | 122.51 | 110.79 | 53.00 | 40.90 | 31.13 | 24.19 | Upgrade
|
| EPS (Diluted) | 122.51 | 110.79 | 53.00 | 40.90 | 31.13 | 24.19 | Upgrade
|
| EPS Growth | 156.08% | 109.03% | 29.60% | 31.39% | 28.70% | 37.88% | Upgrade
|
| Free Cash Flow | - | 418.3 | 251.3 | 580.9 | 408 | 497.6 | Upgrade
|
| Free Cash Flow Per Share | - | 25.29 | 15.19 | 35.12 | 24.67 | 30.09 | Upgrade
|
| Dividend Per Share | - | 20.000 | 16.000 | 12.000 | 9.600 | 7.200 | Upgrade
|
| Dividend Growth | - | 25.00% | 33.33% | 25.00% | 33.33% | 80.00% | Upgrade
|
| Gross Margin | 63.57% | 66.45% | 67.48% | 65.72% | 66.62% | 65.15% | Upgrade
|
| Operating Margin | 17.78% | 21.33% | 19.08% | 17.18% | 16.07% | 13.79% | Upgrade
|
| Profit Margin | 30.08% | 28.04% | 15.06% | 13.19% | 11.70% | 10.28% | Upgrade
|
| Free Cash Flow Margin | - | 6.40% | 4.32% | 11.33% | 9.27% | 12.79% | Upgrade
|
| EBITDA | 1,441 | 1,602 | 1,271 | 1,024 | 846.2 | 683.5 | Upgrade
|
| EBITDA Margin | 21.39% | 24.51% | 21.84% | 19.97% | 19.23% | 17.56% | Upgrade
|
| D&A For EBITDA | 243.2 | 207.8 | 160.6 | 143 | 138.8 | 146.9 | Upgrade
|
| EBIT | 1,198 | 1,394 | 1,111 | 881 | 707.4 | 536.6 | Upgrade
|
| EBIT Margin | 17.78% | 21.33% | 19.08% | 17.18% | 16.07% | 13.79% | Upgrade
|
| Effective Tax Rate | 18.59% | 21.32% | 25.61% | 26.22% | 29.64% | 25.35% | Upgrade
|
| Revenue as Reported | 6,920 | 6,661 | 5,893 | 5,176 | 4,432 | 3,901 | Upgrade
|
| Advertising Expenses | - | 250.4 | 213 | 168.1 | 146.6 | 101 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.